The round was led by European growth capital firm IRIS and Five Arrows, the alternative assets arm of Rothschild & Co. Implicity’s AI-driven platform aggregates and analyzes data from cardiac devices across manufacturers, and has shown a 26% reduction in mortality and a 4% reduction in hospitalizations. The platform is used daily at over 250 medical centers monitoring more than 120,000 patients.
The €35 million investment will accelerate Implicity’s international expansion, with a primary focus on scaling its commercial footprint and operations in the United States, where it has operated from Cambridge, Massachusetts since 2022. It will also fund the continued development of AI capabilities, including next-generation heart failure prediction algorithms.